Ariel Ramirez Navarro
Internal Medicine · Miami, FLNPI 1972755742
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 70.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $318 and has fallen 95.7% since, to $14 in 2025.
Across 9 payments — averaging $49.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$310
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$56
- Edwards Lifesciences$32
- Organogenesis Inc.$30
- Acadia Pharmaceuticals Inc$14
Across 154 payments — averaging $14,677 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1M
- Sanofi US Services Inc.$798K
- Merck$249K
- Genentech, Inc.$168K
- GSK$12K
What the payments were for
- Food & beverage$442100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $310 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $56 |
| Edwards Lifesciences | 1 | $32 |
| Organogenesis Inc. | 1 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$442 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 291 | $158,320 |
| TradjentaLinagliptin | 221 | $110,773 |
| EliquisApixaban | 164 | $95,378 |
| EntrestoSacubitril/Valsartan | 92 | $62,788 |
| TrulicityDulaglutide | 49 | $45,763 |
| OzempicSemaglutide | 24 | $30,400 |
| JardianceEmpagliflozin | 45 | $29,845 |
| FarxigaDapagliflozin Propanediol | 53 | $29,535 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 266 | $26,722 |
| BrilintaTicagrelor | 43 | $18,551 |
| Spiriva RespimatTiotropium Bromide | 31 | $15,602 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 102 | $15,005 |
| Insulin Aspart FlexpenInsulin Aspart | 66 | $9,874 |
| Pregabalin | 137 | $9,841 |
| Clonidine | 58 | $7,768 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.